Cancers & treatments·Regimen libraryChemoradiation

Weekly cisplatin chemoradiation (with pembrolizumab for high-risk disease)

Checked 2026-09-09

Locally advanced cervical cancer (FIGO IB2-IVA); pembrolizumab for FIGO 2014 III-IVA or node-positive

One cycle

weekly × 5-6 · about 5 weeks in total

7-day cycle × 5-6 weekly doses with external beam and brachytherapy (about 5 weeks)IntravenousRadiotherapy

Components

Drug	Dose	Route	Days	Note
Cisplatin Cytotoxic chemotherapy (platinum)	40 mg/m² (maximum 70 mg)	IV	D1
Pembrolizumab (KEYNOTE-A18) Monoclonal antibody (anti-PD-1)	200 mg every 3 weeks × 5, then 400 mg every 6 weeks × 15	IV	D1	every third week
Radiotherapy	45-50.4 Gy external beam plus brachytherapy	Radiotherapy	D1-5

Cycles

5-6 weekly doses with external beam and brachytherapy

7-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

INTERLACE: 6 weeks of induction carboplatin AUC 2 + paclitaxel 80 mg/m² before chemoradiation improved OS.

Used in

Cervical cancer Vulvar cancer Head and neck squamous cell carcinoma

Trials

KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 INTERLACE

Products

CisplatinPembrolizumab

Source

Rose, NEJM 1999; NCCN Cervical Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.